Plain-English translation of NCT06472388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a lower daily dose of everolimus works as well as a higher dose for treating advanced neuroendocrine tumors (slow-growing cancers that start in hormone-producing cells). The study will randomly assign you to take either the lower or higher dose every day and track how well the treatment works and what side effects you experience. Researchers believe the lower dose may fight the cancer just as effectively while causing fewer serious infections and other complications.
Previous research showed that the higher dose of this medication can cause serious infections in about 20% of patients, including dangerous infections that require hospitalization. Early studies suggest the lower dose may be powerful enough to stop cancer growth without these severe side effects, so doctors want to test this idea in a larger group of patients.
You likely qualify if…
You likely don't qualify if…
You will randomly receive either the lower or higher daily dose of the medication to take by mouth continuously. You will continue treatment until your cancer progresses, you develop side effects you cannot tolerate, or you choose to withdraw. Throughout the study, you will have regular imaging scans and blood tests to measure how well the treatment is working and monitor for side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Brazil